Navigation Links
PreHistin ® Allergy Defense Formula Wins 2011 Best New Product Award at ECRM Allergy Show
Date:3/10/2011

IRVINE, Calif., March 10, 2011 /PRNewswire/ -- Cobalis Corp.'s (Pink Sheets: CLSC) http://www.prehistin.com/  [PreHistin® Allergy Defense Formula], the first ever pre-histamine, has taken the coveted 2011 Best New Product Award at the ECRM Cough, Cold and Allergy show held in Orlando, FL, February 28-March 3. PreHistin® regulates overproduction of the key allergen antibody IgE to restore a normal response to both seasonal and year-round allergens, which according to leading US allergist and clinical researcher Dr. Paul H. Ratner, MD is "no allergic response at all!"

"We are very proud that PreHistin® was selected by the country's leading retail and pharmacy buyers as 'Best New Product of the Year' out of a field of thousands of products. In introducing PreHistin® as the world's first PRE-histamine, we have literally created an entirely new category in allergy care, as well as offering the more than 60 million Americans who suffer from seasonal and year-round allergies the first major new option available in years – the opportunity to regulate allergen antibody IgE levels to restore a normal, non-reactive response to allergens, as opposed to treating symptoms after an allergic reaction has started. We thank the retailers and distributors who attended this show for awarding us this great honor and recognition," said Marty Marion, CEO of Cobalis Corp.

PreHistin® is now on shelves at one of the nation's two largest drugstore chains, and is expected to be on pharmacy and grocery shelves across the country very quickly. Indoor and outdoor allergy sufferers, who need relief seasonally or year-round, can feel the benefits of PreHistin® in as little as a few weeks of regular use. The all-natural formula of PreHistin® is a lozenge dissolved under the tongue and then swallowed twice a day during allergy season, or year-round for those who suffer from indoor allergens like dust, mold and pet dander.

"I recommend that all of my patients who suffer from allergies use PreHistin®," said allergist Dr. Paul Ratner. "Not only is the product safe but it is extremely effective, completely non-drowsy, and has no side effects."

Readers who are interested in more information should visit www.prehistin.com. To arrange a media interview with Dr. Paul Ratner please contact Nancy Trent or Pam Wadler at 212-966-0024 or send an email to pam@trentandcompany.com.

ABOUT PREHISTIN® ALLERGY DEFENSE FORMULA

PreHistin® Allergy Defense Formula is a unique, patented cobalamin complex product that helps rebalance the immune system to lower allergen antibody IgE levels, and regulate the release of symptom-linked histamine which is linked to the onset of symptoms such as sneezing, itchy watery eyes, runny nose and nasal congestion. PreHistin® is a cherry-flavored lozenge that is dissolved under the tongue and then swallowed twice a day, usually starting before the allergy season, or taken daily for those suffering from year-round allergies. PreHistin® has no known side effects, is 100% non-drowsy, and has no contraindications with any other medications. In clinical trials on thousands of allergy sufferers, PreHistin® was shown to be safe and effective in reducing nasal symptoms.

ABOUT COBALIS CORP.—PREHISTIN®

Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin® Allergy Defense Formula, "The World's First Pre-Histamine", is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin® is now available without prescription for both long-term and daily use.

For PreHistin® product information please visit www.PreHistin.com or call toll free

1-877-4POLLEN (1-877-476-5536). For additional company information please visit the corporate website at www.Cobalis.com. CONTACTCobalis Corp.949-260-0123Chas Radovich, PresidentMartin Marion, CEOinfo@cobalis.com
'/>"/>

SOURCE Cobalis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cobalis Corp. Receives $415,000 First Purchase Order from Major Retail Pharmacy for PreHistin® Allergy Defense Formula
2. Sams Club® Offers Free Allergy Health Screenings
3. Good Clostridia in the Gut Protect from Allergy and Autoimmunity
4. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
5. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
6. Cetero Research Leads Industry in Human Allergy Models
7. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
8. National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production
9. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
10. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
11. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... Feb. 23, 2017 Research and Markets has ... Strategies - 2016" report to their offering. ... The latest research Fibromyalgia Drugs ... benchmarks in the global Fibromyalgia market. The research answers ... drugs marketed for Fibromyalgia and their clinical attributes? How are they ...
(Date:2/23/2017)... , February 23, 2017 ... Market by Product (X-ray Imaging Digital, Analog), MRI (Closed, ... (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) ... report studies the global market over the forecast period ... reach ~USD 36.43 Billion by 2021, at a CAGR ...
Breaking Medicine Technology:
(Date:2/23/2017)... Los Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... the first two episodes of WE TV’s “Mama June: From Not to Hot,” which ... of TV notable, “Mama” June Shannon, known to millions from the 2012 reality television ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, ... clients already in the state and in nearby New Hampshire, Massachusetts and Canada, ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... new, interactive publication where generations converge and explore the world from different perspectives. ... Dialog Magazine enables readers to gain understanding, increase empathy, and find greater happiness. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current Meditation , ... begin franchising throughout the U.S. starting this spring. Current Meditation focuses on “meditation ... meditation mainstream. Current Meditation will be the first meditation concept in the U.S. ...
Breaking Medicine News(10 mins):